Establishments and authorised organisations shall implement a procedure for the withdrawal of advanced therapy medicinal products prepared on an ad hoc basis in accordance with the rules of good practice provided for in Article L. 5121-5 and including a description of the responsibilities and measures to be taken.
The responsible person undertakes and coordinates the necessary actions. It shall immediately notify the Director General of the Agence nationale de sécurité du médicament et des produits de santé of any withdrawal measure. It shall send a copy of this notification to the Director General of the Agence de la biomédecine.